Open Nav

Please submit your session questions in advance at

Fibrocell Science, Inc.

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is also developing FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NASDAQ: XON), a leader in synthetic biology.

  • Date:Monday, February 11
  • Time:9:45 AM - 10:00 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:22478
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Engage & excite on progress of Fibrocell’s pipeline addressing unmet needs of rare skin diseases
  • Company
  • Company HQ City:Exton
  • Company HQ State:Pennsylvania
  • Company HQ Country:United States
  • Ticker:FCSC
  • Exchange:NASDAQ
  • CEO/Top Company Official:John Maslowski
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development:FCX-007 for treatment of recessive dystrophic epidermolysis bullosa (RDEB)
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:Fibrocell is also developing FCX-013, its clinical stage candidate for the treatment of moderate to severe localized scleroderma—a chronic, debilitating genetic skin disorder with no FDA approved therapies.
John Maslowski
Fibrocell Science